Clinical Trials Logo

Filter by:
NCT ID: NCT06162234 Recruiting - High Myopia Clinical Trials

Wuhan High Myopia Study

LOVE-WH
Start date: December 25, 2023
Phase:
Study type: Observational [Patient Registry]

The study aims to observe the long-term changes of ocular(especially fundus) structure and visual function in patients with high myopia, so as to provide evidence for the prevention, diagnosis and prognosis of high myopia.

NCT ID: NCT06162169 Completed - Healthy Subjects Clinical Trials

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Start date: November 25, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole, rifampicin, and omeprazole in healthy subjects.

NCT ID: NCT06161987 Recruiting - Clinical trials for Acute Decompensated Heart Failure

EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF

EACH-ADHF
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

EACH-ADHF: Early Comprehensive Rehabilitation in patients with ADHF study is a multi-center, parallel-group, randomized controlled trial designed to evaluate the effects of the early comprehensive rehabilitation including exercise and inspiratory muscle training, over a period of 6 weeks, on the quality of life of patients with ADHF.

NCT ID: NCT06161948 Recruiting - Stroke Clinical Trials

Time-restricted Enteral Nutrition Versus Continuous Enteral Nutrition in Patients With Severe Stroke

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

In patients with severe stroke whose GCS score is ≤12 points or NIHSS score is ≥11 points, to evaluate whether time-restricted enteral nutrition can improve the incidence of poor 90-day prognosis (mRS ≥3 points) compared with continuous enteral nutrition.

NCT ID: NCT06161922 Recruiting - Clinical trials for HER2-positive Breast Cancer

Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy

Start date: October 26, 2023
Phase:
Study type: Observational

This is a non-interventional observational, multi-center cohort study to evaluate patient-reported outcomes in Chinese HER2+ early breast cancer patients undergoing (neo) adjuvant anti-HER2 based therapy and describe changes over time, from baseline to 12 months.

NCT ID: NCT06161909 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma Thoracic Stage III

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

Esophageal cancer (EC) is one of the most common malignant tumors of the digestive tract in human beings. Most cases of EC are initially diagnosed in an advanced stage of the disease. Considering the lack of effective adjuvant therapies after surgery for locally advanced esophageal squamous carcinoma. And with the encouraging preliminary results of PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC), postoperative adjuvant immunotherapy for esophageal squamous carcinoma seems to be feasible. The main objective of this study was the efficacy of postoperative adjuvant therapy with sintilimab in patients with ESCC radically resected after neoadjuvant chemoimmunotherapy.

NCT ID: NCT06161870 Recruiting - Severe Infection Clinical Trials

Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare the clinical efficacy of individualized dosing based on the population pharmacokinetics (PK) model and empirical dosing of vancomycin in participants with severe infections. It aims to answer whether individual vancomycin dosing based on population PK model is superior to empirical dosing in terms of clinical efficacy and safety. Participants will be randomly divided into experimental group and control group. The experimental group will be guided by the population PK model for individual dosing, and the control group will be given empirical dosing. Demographic data, clinical characteristics of participants, and their trough concentrations (Cmin) and peak concentrations (Cmax) of vancomycin will be collected. Area under the concentration curve (AUC24) of participants will be calculated using the first-order PK equation. Researchers will compare experimental group and control group to see if individual vancomycin dosing based on population PK model is superior to empirical dosing in terms of clinical efficacy and safety.

NCT ID: NCT06161844 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

Start date: February 23, 2024
Phase: Phase 3
Study type: Interventional

To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.

NCT ID: NCT06161779 Recruiting - Clinical trials for Head and Neck Cancers - Hypopharyngeal

Submental Flap for the Reconstruction of Hypopharyngectomy

SMFRLPD
Start date: February 16, 2023
Phase: N/A
Study type: Interventional

The goal of this observational study is to assess the safety and efficacy of submental artery island flap (SMAIF) in the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer. The main questions it aims to answer are: - The survival of SMAIF and the recovery of laryngeal function. - The oncologic outcomes of SMAIF comparing with other reconstructions or radiotherapy. Participants will underwent partial laryngectomy and hypopharyngectomy and reconstruction of SMAIF. Postoperative adjuvant radiotherapy will be recommented when adverse pathologic features were noted.

NCT ID: NCT06161701 Recruiting - Nephrotic Syndrome Clinical Trials

Steroid Diabetes in Patients With Kidney Disease

Start date: January 10, 2024
Phase:
Study type: Observational

If steroid diabetes is not recognized in time, it will cause irreversible damage to the body. Nephropathy patients are more likely to have steroid diabetes ,the incidence rate up to 25%,due to hypoalbuminemia, high-dose hormone and other reasons, so they need to be closely followed up, identified and intervened in time.